Acrivastine-BW825C-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAcrivastineCat. No.: HY-B1510CAS No.: 87848-99-5Synonyms: BW825C分式: CHNO分量: 348.44作靶点: Histamine Receptor作通路: GPCR/G Protein; Immunology/Inflammation; NeuronalSignaling储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-2

2、0C 1 month溶解性数据体外实验 DMSO : 10.45 mg/mL (29.99 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.8699 mL 14.3497 mL 28.6993 mL5 mM 0.5740 mL 2.8699 mL 5.7399 mL10 mM 0.2870 mL 1.4350 mL 2.8699 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Acrivastine (BW8

3、25C)于治疗过敏性炎的短效histamine 1受体拮抗剂。体内研究Acrivastine (usually 8mg three times daily) is an effective and well tolerated antihistamine in the treatment ofchronic urticaria and allergic rhinitis. Acrivastine is more effective than placebo and similar in efficacy toclemastine or terfenadine in the treatment

4、of seasonal allergic rhinitis. In the treatment of dermatoses in1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEwhich histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similarto that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cypro

5、heptadine or terfenadine.Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishablefrom that with placebo or terfenadine 1. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonalallergic rhinitis with significant improvements in the sympto

6、m scores for sneezing, running nose and thecalculated overall score. In addition, 8 mg acrivastine reduces the symptom scores for watery eyes and itchythroat. Acrivastine is both well tolerated and effective in the treatment of seasonal allergic rhinitis 2.REFERENCES1. Brogden RN, et al. Acrivastine

7、. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and relateddisorders. Drugs. 1991 Jun;41(6):927-40.2. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonalallergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.McePdfHeightCaution: Product has not been fully validated for medical applications.For research